Navigation Links
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:7/20/2009

months from our non-nucleoside polymerase inhibitor and protease inhibitor programs, we are closer to achieving our ultimate goal of developing novel combinations of direct-acting antivirals for the treatment of hepatitis C."

The company plans to report the full data set from this study at a scientific meeting later this year.

About IDX184

IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide prodrug, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing of drug.

Conference Call Information

Idenix will hold a conference call and webcast today at 4:30 p.m. ET. To access the call please dial 800-774-5358 U.S./Canada or 706-758-9475 International and enter passcode 20088902 or to listen to a live webcast and view accompanying slides, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. A replay of the call will also be available from 6:30 p.m. ET on July 20, 2009 until August 3, 2009 12:00 a.m. ET. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API) today updates the ... Qionglai Facility (QLF). The Company ... (GMP) dataset for China Food & Drug Administration,s ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Some of the world,s largest pharmaceutical firms announced this ... in order to slash costs and keep investors happy, exposing ... AstraZeneca were the first to announce further job cuts with ... has already seen an extraordinary amount of job cuts over ...
... Md., Feb. 29, 2012  MedImmune today announced that ... approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for ... early in the second quarter of last year.  ... approved by the FDA. All other ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3
(Date:8/29/2014)... The University of Houston Graduate College of Social Work is ... $1.25 million grant from the National Institute of Drug Abuse ... the long-term use and health consequences of heroin use. Additionally, ... support future research endeavors. , Heroin use has ... from prescription pain medication abuse to the cheaper and more ...
(Date:8/29/2014)... Lincoln, R.I. (PRWEB) August 29, 2014 A home ... can crop up if unaddressed. That’s why Amica Insurance is sharing ... The National Safety Council suggests taking the following safety measures: , ... and disinfectants – in their original containers, and keep them away ... on a wall bracket near an exit. , Bathroom ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
Breaking Medicine News(10 mins):Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2
... (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced ... PLC and unconditionally retract the announcement made earlier this ... Jensen, Chief Science Officer of Bridge BioResearch PLC, will ... , , About GENova Biotherapeutics Inc. , ...
... MISSION VIEJO, Calif., Sept. 18 The Ensign Group, Inc. ... group of skilled nursing, rehabilitative care services and assisted living companies, ... cash dividend of $0.045 per share of Ensign common stock, payable ... of September 30, 2009. Ensign has been a dividend-paying company since ...
... - revenues increase by 21% over ... figures are in Canadian dollars unless otherwise noted), , ... Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today ... 30, 2009. , "We had a very successful year in ...
... HAYWARD, Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: ... market, today announced that it will present at the Maxim Group ... the Grand Hyatt New York Hotel in New York, NY. ... September 29, 2009. Stephen J. Fanning, Chairman, President and Chief ...
... SAN CARLOS, Calif., Sept. 18 Nektar Therapeutics (Nasdaq: ... Global Life Sciences Conference in New York at the Grand Hyatt Hotel ... , The presentation will be accessible via a Webcast through ... Nektar website: http://www.nektar.com . This Webcast will be available ...
... be a nasal spray, followed shortly by injectable one: CDC ... doses of the H1N1 swine flu vaccine will start shipping ... U.S. health officials said Friday. , These first 3.4 million ... FluMist. , "There is a good antibody response to the ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2009 Year-End Results 2Health News:Bioniche Reports Fiscal 2009 Year-End Results 3Health News:Bioniche Reports Fiscal 2009 Year-End Results 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 5Health News:Bioniche Reports Fiscal 2009 Year-End Results 6Health News:Bioniche Reports Fiscal 2009 Year-End Results 7Health News:Bioniche Reports Fiscal 2009 Year-End Results 8Health News:Bioniche Reports Fiscal 2009 Year-End Results 9Health News:Bioniche Reports Fiscal 2009 Year-End Results 10Health News:Bioniche Reports Fiscal 2009 Year-End Results 11Health News:Bioniche Reports Fiscal 2009 Year-End Results 12Health News:Bioniche Reports Fiscal 2009 Year-End Results 13Health News:Bioniche Reports Fiscal 2009 Year-End Results 14Health News:Bioniche Reports Fiscal 2009 Year-End Results 15Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 3Health News:1st Doses of Swine Flu Vaccine Set for Early October 4
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
Medicine Products: